Establishment Labs (NASDAQ:ESTA) Announces Quarterly Earnings Results, Misses Expectations By $0.34 EPS

Establishment Labs (NASDAQ:ESTA) released its quarterly earnings data on Wednesday. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.34), Zacks reports. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The business had revenue of $44.51 million during the quarter, compared to the consensus estimate of $44.45 million.

Establishment Labs Price Performance

NASDAQ:ESTA opened at $38.57 on Thursday. The firm’s 50-day simple moving average is $37.50 and its 200 day simple moving average is $41.37. Establishment Labs has a 52 week low of $28.16 and a 52 week high of $60.12. The firm has a market cap of $1.08 billion, a price-to-earnings ratio of -15.11 and a beta of 1.12. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62.

Analyst Ratings Changes

Separately, Stephens raised shares of Establishment Labs to a “strong-buy” rating in a report on Monday, December 2nd. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $60.60.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.